%0 Journal Article %1 Kassai2003 %A Kassai, Behrouz %A Gueyffier, François %A Boissel, Jean-Pierre %A Boutitie, Florent %A Cucherat, Michel %D 2003 %J Journal of clinical epidemiology %K 80andover Adult Aged AntihypertensiveAgents AntihypertensiveAgents:therapeuticuse Disease-FreeSurvival DrugAdministrationSchedule Female Humans Hypertension Hypertension:drugtherapy LifeExpectancy LifeTables Male MiddleAged ResearchDesign RiskAssessment TreatmentOutcome RCT %N 10 %P 977-82 %T Absolute benefit, number needed to treat and gain in life expectancy: which efficacy indices for measuring the treatment benefit? %U http://www.ncbi.nlm.nih.gov/pubmed/14568629 %V 56 %X The absolute benefit (AB) is extensively used to summarize the results of clinical trials. As the AB depends directly on the patient's baseline risk, therapeutic decisions based on AB tend to favor patients at high risk. To evaluate the consequences of this decision's procedure for life-long therapy, we compare the AB with the gain in event-free life expectancy in a simulated hypertensive population. Our results show that the AB goes through a maximum and then declines as the duration of treatment increases. The amplitude of the variation of AB is independent of the baseline risks but the maximum is reached more quickly in the high-risk patients. Considering the gain in event-free life expectancy, low-risk patients benefit more than high-risk patients do, at the expense of a longer treatment exposure. The interpretation of the AB changes depending on follow-up.

@article{Kassai2003, abstract = {The absolute benefit (AB) is extensively used to summarize the results of clinical trials. As the AB depends directly on the patient's baseline risk, therapeutic decisions based on AB tend to favor patients at high risk. To evaluate the consequences of this decision's procedure for life-long therapy, we compare the AB with the gain in event-free life expectancy in a simulated hypertensive population. Our results show that the AB goes through a maximum and then declines as the duration of treatment increases. The amplitude of the variation of AB is independent of the baseline risks but the maximum is reached more quickly in the high-risk patients. Considering the gain in event-free life expectancy, low-risk patients benefit more than high-risk patients do, at the expense of a longer treatment exposure. The interpretation of the AB changes depending on follow-up.}, added-at = {2023-02-03T11:44:35.000+0100}, author = {Kassai, Behrouz and Gueyffier, François and Boissel, Jean-Pierre and Boutitie, Florent and Cucherat, Michel}, biburl = {https://www.bibsonomy.org/bibtex/299b47deb830280ad47180396bfc86776/jepcastel}, interhash = {c599de19bab4c881a88b9a479237cd3d}, intrahash = {99b47deb830280ad47180396bfc86776}, issn = {0895-4356}, journal = {Journal of clinical epidemiology}, keywords = {80andover Adult Aged AntihypertensiveAgents AntihypertensiveAgents:therapeuticuse Disease-FreeSurvival DrugAdministrationSchedule Female Humans Hypertension Hypertension:drugtherapy LifeExpectancy LifeTables Male MiddleAged ResearchDesign RiskAssessment TreatmentOutcome RCT}, month = {10}, note = {3539<m:linebreak></m:linebreak>Mesures de contrast}, number = 10, pages = {977-82}, pmid = {14568629}, timestamp = {2023-05-04T09:00:45.000+0200}, title = {Absolute benefit, number needed to treat and gain in life expectancy: which efficacy indices for measuring the treatment benefit?}, url = {http://www.ncbi.nlm.nih.gov/pubmed/14568629}, volume = 56, year = 2003 }